Researchers at CZ Biohub SF and Stanford have developed unique fusion proteins that have broad therapeutic benefits for the treatment of infection by existing and future coronaviruses.
Stanford scientists have developed broadly neutralizing antibodies against sarbecoviruses , including SARS-CoV-2 related Clade 1b, SARS-CoV related Clade 1a and Clade 3 viruses, paving the way for future vaccines and therapeutics.